Clinical Trial

Assessment of Thyroid Dysfunction in Patients Undergoing Haemodialysis at Sohag University Hospital

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 15, 2025 (before its estimated October 13, 2025 completion). Its status may not reflect the trial's current state.
Summary
Thyroid dysfunction is a prevalent endocrine disorder that significantly impacts the health of patients with chronic kidney disease (CKD), particularly those undergoing dialysis. The prevalence of thyroid dysfunction in dialysis patients has been reported to range from 20% to 60%, highlighting the need for routine screening and management in this vulnerable group (Kuo et al., 2024). Thyroid hormones play a crucial role in regulating various physiological processes, and their dysregulation can lead to complications such as cardiovascular disease, anemia, and impaired quality of life, which are particularly concerning in the dialysis population (Smith et al., 2024). The relationship between CKD and thyroid dysfunction is complex and multifactorial. Uremic toxins can interfere with the hypothalamic-pituitary-thyroid axis, leading to alterations in thyroid hormone production and metabolism. Recent studies have shown that inflammation and oxidative stress associated with CKD can further exacerbate thyroid dysfunction (Johnson et al., 2024). Understanding these mechanisms is essential for developing effective management strategies for thyroid health in dialysis patients.
Trial Details
NCT Number NCT07022236
Lead Sponsor Sohag University
Conditions Dialysis; Complications
Enrollment 1 participants
Start Date 2025-04-13
Primary Completion 2025-10-13 (estimated)
Study Completion 2025-10-30 (estimated)
Updated on ClinicalTrials.gov 2025-06-15